Antidysrhythmic drug therapy for the termination of stable, monomorphic ventricular tachycardia: a systematic review.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Journal titleEmergency medicine journal : EMJ
Publication Begin page161
Publication End page7
MetadataShow full item record
AbstractWe performed a systematic review of the literature to compare the efficacy of different drug therapies for the termination of stable, monomorphic ventricular tachycardia (VT).
We searched EMBASE, MEDLINE and Cochrane for trials from 1965 through July 2013 using a search strategy derived from the following clinical question in PICO format:
Adults (≥18 years) with stable monomorphic VT;
Intravenous antidysrhythmic drug; Comparator: Intravenous lidocaine or amiodarone;
Termination of VT. For all drug comparisons, we calculated relative risks (RR; 95% CI) and number needed to treat (NNT, 95% CI) between drugs. We also evaluated the methodological quality of the studies.
Our search yielded 219 articles by PubMed and 390 articles by EMBASE. 3 prospective studies (n=93 patients) and 2 retrospective studies (n=173 patients) met our inclusion and exclusion criteria. From the prospective studies, RR of VT termination of procainamide versus lidocaine was 3.7 (1.3-10.5); ajmaline versus lidocaine, RR=5.3 (1.4-20.5); and sotalol versus lidocaine, RR=3.9 (1.3-11.5). From the retrospective studies: procainamide versus lidocaine, RR=2.2 (1.2-4.0); and procainamide versus amiodarone RR=4.3 (0.8-23.6). All 5 reviewed studies had quality issues, including potential bias for randomisation and concealment.
Based on limited available evidence from small heterogeneous human studies, for the treatment of stable, monomorphic VT, procainamide, ajmaline and sotalol were all superior to lidocaine; amiodarone was not more effective than procainamide.
CitationdeSouza IS, Martindale JL, Sinert R. Antidysrhythmic drug therapy for the termination of stable, monomorphic ventricular tachycardia: a systematic review. Emerg Med J. 2015 Feb;32(2):161-7. doi: 10.1136/emermed-2013-202973. Epub 2013 Sep 16. PMID: 24042252.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
- Best Clinical Practice: Emergency Medicine Management of Stable Monomorphic Ventricular Tachycardia.
- Authors: Long B, Koyfman A
- Issue date: 2017 Apr
- Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: an historical multicenter comparison.
- Authors: Marill KA, deSouza IS, Nishijima DK, Senecal EL, Setnik GS, Stair TO, Ruskin JN, Ellinor PT
- Issue date: 2010 Mar
- Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia.
- Authors: Gorgels AP, van den Dool A, Hofs A, Mulleneers R, Smeets JL, Vos MA, Wellens HJ
- Issue date: 1996 Jul 1
- Intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment?
- Authors: Tomlinson DR, Cherian P, Betts TR, Bashir Y
- Issue date: 2008 Jan
- Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans.
- Authors: Kidwell GA, Greenspon AJ, Greenberg RM, Volosin KJ
- Issue date: 1993 Jan